Skip to main content

Table 2 Survival analysis of patients in the validated group

From: Development and validation of a novel circular RNA as an independent prognostic factor in acute myeloid leukemia

Variables

Univariate analysis

Multivariate analysis

P value

HR (95%CI)

P value

HR(95%CI)

circRNA

0.003

1.706 (1.195, 2.436)

0.023

1.592 (1.067, 2.377)

Age

< 0.001

2.125 (1.484, 3.042)

0.006

1.792 (1.183, 2.714)

WBC

0.024

1.003 (1, 1.006)

0.012

1.004 (1.001, 1.007)

ELN favorable genotype

0.004

0.532 (0.345, 0.82)

0.089

0.648 (0.393, 1.069)

DNMT3A

0.042

1.648 (1.017, 2.668)

0.008

2.031 (1.205, 3.423)

IDH1

0.199

1.353 (0.853, 2.148)

0.709

0.887 (0.471, 1.667)

IDH2

0.396

0.772 (0.424, 1.404)

0.265

0.706 (0.383, 1.302)

Treatment

 HAA vs. DA

0.044

0.598 (0.363, 0.987)

0.165

0.652 (0.356, 1.192)

 IA vs. DA

< 0.001

0.485 (0.325, 0.723)

0.011

0.554 (0.351, 0.875)

  1. CircRNA represents hsa_circ_0075451 high expressers vs. low expressers. European LeukemiaNet (ELN) favorable genotype represents NPM1 mutant and FLT3-ITD negative or double allele CEBPA mutations
  2. WBC white blood cell count, HAA homoharringtonin-based treatment (homoharringtonin 2 mg/m2/day for 3 days, cytarabine 75 mg/m2 twice daily for 7 days, aclarubicin 12 mg/m2 daily for 7 days) regiment, DA daunorubicin (45 mg/m2 daily for 3 days and cytarabine 100 mg/m2 daily for 7 days), IA idarubicin (8–10 mg/m2 daily for 3 days and cytarabine 100 mg/m2 daily for 7 days)
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us